NCT06736327招募中1 期
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 180
- 试验地点
- 3
- 主要终点
- Evaluate the incidence of adverse events (AEs)
研究概览
简要总结
This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.
详细描述
This study is a multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors. The study includes a dose-escalation phase, a dose-expansion phase, and an indication-expansion phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants between 18 and 75 years old.
- •Histologically or cytologically confirmed advanced solid tumors for which standard treatment either does not exist or has proven ineffective or intolerable.
- •Subjects should ideally provide a tumor tissue sample for biomarker testing during the screening period.
- •Has at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- •ECOG performance status score of 0 or
- •Expected survival of at least 12 weeks.
- •Has adequate hematopoietic, renal and hepatic functions.
- •Have recovered to grade ≤ 1 of prior anti-cancer treatment toxicities.
- •Male and female subjects must agree to use highly effective contraceptive methods throughout the study.
- •Subjects must voluntarily enter the study, sign the informed consent form, and be able to comply with the visits and procedures.
排除标准
- •Subjects with known active CNS metastases, carcinomatous meningitis, leptomeningeal metastases, or spinal cord compression.
- •Subjects with other malignancies within 5 years before the first dose.
- •Any severe and/or uncontrolled concurrent disease that may interfere with the subject's participation in the study.
- •Active hepatitis B, or hepatitis C; active tuberculosis, or human immunodeficiency virus (HIV) test positive, or known acquired immunodeficiency syndrome (AIDS).
- •History of allergy to any component of SKB500 or history of severe hypersensitivity reactions to other monoclonal antibodies.
- •Subjects with a history of interstitial lung disease, non-infectious pneumonia, or other pulmonary diseases significantly affecting lung function.
- •History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
- •Uncontrolled pleural effusion, ascites, or pericardial effusion.
- •Have received ADCs with the same target or the same toxins.
- •Have received chemotherapy, small molecule targeted therapy, and traditional Chinese medicine preparations within 14 days or 5 half-lives before the first dose; have received any immunotherapy, large molecule anticancer drug treatment, or more than 30% bone marrow radiation or extensive radiotherapy within 28 days before the first dose.
- •Have undergone major surgery or severe trauma within 28 days before the first dose.
- •Have received other clinical trial medications within 28 days before the first dose.
- •Has previously received anti-cancer or live vaccines within 28 days before the first dose
- •Have received systemic steroids or other immunosuppressive treatments within 14 days before the first dose.
- •Have received potent CYP3A4 inhibitors, inducers, or BCRP inhibitors within 14 days or 5 half-lives before the first dose.
- •Pregnant or lactating female.
- •Any disease or condition that, in the investigator's opinion, would compromise subject safety or interfere with study assessments.
研究组 & 干预措施
SKB500
Experimental
Subjects will receive SKB500 once every three weeks (Q3W).
干预措施: SKB500 (Drug)
结局指标
主要结局
Evaluate the incidence of adverse events (AEs)
时间窗: Up to 3 years
Evaluate the incidence of serious adverse events (SAEs)
时间窗: Up to 3 years
Evaluate the incidence of treatment related adverse events (TRAEs)
时间窗: Up to 3 years
Evaluate the incidence of dose-limiting toxicities (DLTs)
时间窗: Day 1 to Day 21 in Cycle 1 in the dose escalation part
次要结局
- Investigate the antitumor activity of SKB500(Up to 3 years)
- To evaluate the AUC of SKB500(Up to 3 years)
- To evaluate the Tmax of SKB500(Up to 3 years)
- To evaluate the Cmax of SKB500(Up to 3 years)
- To evaluate the Cmin of SKB500(Up to 3 years)
- To evaluate the t1/2 of SKB500(Up to 3 years)
- To evaluate the CL of SKB500(Up to 3 years)
- To evaluate the Vz of SKB500(Up to 3 years)
- To evaluate the ADA of SKB500(Up to 3 years)
研究者
研究点 (3)
Loading locations...
相似试验
撤回
1 期
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese ParticipantsSolid TumorsNCT05644626BeiGene
终止
1 期
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid TumorsSolid TumorNCT05494762BeiGene55
招募中
1 期
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCNon Small Cell Lung CancerNCT05430386Jiangsu Hansoh Pharmaceutical Co., Ltd.174
已完成
1 期
A Study of Single and Multiple Dose Administration of LP-001 in Healthy SubjectsMyelodysplastic Syndrome (MDS)NCT06294275Longbio Pharma68
已完成
1 期
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabGastroesophageal Junction CancerBreast CancerGastric CancerNCT04276493BeiGene71